Leveraging the proprietary STAR (selective targeted RNA delivery) LNP technology platform, we could deliver a wide range of RNA-based modalities to specific orangs and tissues, and more precisely, to individual cell types. This cutting-edge approach allows us to precisely target and address complex medical challenges.

In addition to our pioneering LNP technology, we have established several other technology platforms: linear mRNA and circular RNA engineering. These have paved the way for next-generation RNA therapies.

With our end-to-end pilot scale production capabilities, we are able to accelerate the translation of our discoveries from the laboratory to the clinic. Our leading preventive vaccine program is about to enter clinical trials in 2024.